| http://www.w3.org/ns/prov#value | - LifeSciences - In today???s monitoring environment which has been enabled by recent guidance and reflection papers by regulators on clinical risk-based approaches to monitoring clinical study quality, monitoring activities should now be designed to track two types of risks identified in the clinical risk assessmentSpeakers: Michael Macri, Director, Strategic Services, inVentiv Health ClinicalJeffr
|
